Division of Roche
Latest From Tanox Inc.
Biotech licensers often retain an option to co-promote when out-licensing their products. But how often are these options actually exercised?
Shire's $2.6 billion all-cash acquisition of its Vyvanse partner New River Pharmaceuticals is no surprise. The original deal signed by the companies in 2005 engineered Shire's motivation to buy New River in the event Vyvanse became a success. New River's unusually consolidated ownership allowed it to remain independent until the eve of Vyvanse's approval and secure a top-drawer takeout valuation.
We present another installment of our quarterly review of dealmaking-for October-December 2006. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.
Our review of top stories of 2006 touches on a variety of subjects, but the majority drive to one über-theme: the pipeline challenge. Products suddenly disappeared into the generic abyss, with nothing new to take their places. Compounds likely to succeed didn't. The price of in-licensable products soared. Even relatively good news for pipelines largely reflected the absence of further bad news: the safety squabbles did not result in higher hurdles to product approvals.
- Large Molecule
- Therapeutic Areas
- Tanox Biosystems Inc.
- North America
- Parent & Subsidiaries
- Senior Management
Zhengbin Yao, PhD, VP, Research
Gregory P Guidroz, VP, Fin.
- Contact Info
Phone: (713) 578-4000
10555 Stella Link
Houston, TX 77025-5631
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.